On September 18, 2019 NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), reported its participation and poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress on September 27 – October 1, 2019 at Fira Gran Via, Av. Joan Carles, 64, 08908 L’Hospitalet de Llobregat, Barcelona, Spain (Press release, Noxxon, SEP 18, 2019, View Source [SID1234539621]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Title: Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer

The poster will be presented on Sunday, September 29 from 12.00-01.00 p.m. CEST in Hall 4 and the authors will be available for questions. The poster will also be uploaded to the NOXXON website.

The abstract which is based on an earlier interim dataset will be published on Monday, September 23, at 00.05 a.m. CEST on the ESMO (Free ESMO Whitepaper) website.

Aram Mangasarian, CEO of NOXXON, and Dr. Jarl Ulf Jungnelius, CMO, will host a webcast poster presentation on September 30, 2019, at 09.00 a.m. CEST, to discuss the data from this trial and its relevance for further clinical development of NOX-A12. The presentation will be followed by a Q&A session. To join the webcast, please send an email to [email protected].